Home Online Features AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
Hand-out
Press Releases
Azurity Pharmaceuticals, Inc.  
November 14, 2024

AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS

WOBURN, Mass., Nov. 14, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social